Estamos no ar no !
Saiba mais
Elevation Oncology
Deslistada
ELEV foi retirado da bolsa em 22 de julho de 2025.
Sobre: Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
Funcionários: 34
Notícias
Positiva
Neutra
Negativa
Sentimento
3 meses
Positiva
0%
Neutra
0%
Negativa
0%
Gráficos de preços implementados com Lightweight Charts™